DBPR108
Dipeptidyl-peptidase 4 inhibitor
Also Known As:
(2S,4S)-4-fluoro-1-(2-((2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino)acetyl)pyrrolidine-2-carbonitrile
Networked: 2
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Type 2 Diabetes Mellitus (MODY)
01/01/2020
- " This study was to evaluate the efficacy and safety of DBPR108 monotherapy in type 2 diabetes mellitus (T2DM).Methods: This was a 12-week, double-blind, placebo-controlled phase II clinical trial. " 01/01/2020
- " Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial." 11/01/2022
- " To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, as an add-on therapy in patients with type 2 diabetes (T2D) that is inadequately controlled with metformin. " 11/01/2022
- " Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial."
|
| 2. | Weight Gain
|
| 3. | Hypoglycemia (Reactive Hypoglycemia)
|
|
Related Drugs and Biologics
Related Therapies and Procedures